… acquire OT-58, an investigational human enzyme replacement therapy with disease … application for CMA consideration in Europe. Secondary efficacy endpoints include the … exclusivity periods and intellectual property rights of third parties; risks associated …
The post Retrophin Reports Third Quarter 2020 Financial Results first appeared on TheEuropeanTimes.INFO.